Mickaël Riou

Dr. Mickaël Riou


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2021 in Viruses
Verified
Journal Article
Open access
PDF file
KCKris De Clercq
Kris De Clercq
LVLeen Vandaele
Leen Vandaele
TVTine Vanbinst
Tine Vanbinst
MRMickaël Riou
Mickaël Riou
IDIsra Deblauwe
Isra Deblauwe
ILIlse De Leeuw
Ilse De Leeuw
Transmission of bluetongue (BT) virus serotype 8 (BTV-8) via artificial insemination of contaminated frozen semen from naturally infected bulls was investigated in two independent experiments. Healthy, BT negative heifers were hormonally synchronized and artificially inseminated at oestrus. In total, six groups of three heifers received semen from four batches derived from three bulls naturally infected with BTV-8. Each experiment included one control heifer that was not inseminated and that remained BT negative throughout. BTV viraemia and seroconversion were determined in 8 out of 18 inseminated heifers, and BTV was isolated from five of these animals. These eight heifers only displayed mild clinical signs of BT, if any at all, but six of them experienced pregnancy loss between weeks four and eight of gestation, and five of them became BT PCR and antibody positive. The other two infected heifers gave birth at term to two healthy and BT negative calves. The BT viral load varied among the semen batches used and this had a significant impact on the infection rate, the time of onset of viraemia post artificial insemination, and the gestational stage at which pregnancy loss occurred. These results, which confirm unusual features of BTV-8 infection, should not be extrapolated to infection with other BTV strains without thorough evaluation. This study also adds weight to the hypothesis that the re-emergence of BTV-8 in France in 2015 may be attributable to the use of contaminated bovine semen.

1 November 2023 in Hepatology Communications
Verified
Journal Article
Open access
NLNancy León-Janampa
Nancy León-Janampa
ICIgnacio Caballero-Posadas
Ignacio Caballero-Posadas
CBCéline Barc
Céline Barc
FDFrançois Darrouzain
François Darrouzain
AMAlain Moreau
Alain Moreau
JMJulien Marlet
Julien Marlet
Background: Hepatitis E virus (HEV) is a zoonotic virus transmitted by pig meat and responsible for chronic hepatitis E in immunocompromised patients. It has proved challenging to reproduce this disease in its natural reservoir. We therefore aimed to develop a pig model of chronic hepatitis E to improve the characterization of this disease. Methods: Ten pigs were treated with a tacrolimus-based regimen and intravenously inoculated with HEV. Tacrolimus trough concentration, HEV viremia, viral diversity, innate immune responses, liver histology, clinical disease and biochemical markers were monitored for 11 weeks post-infection (p.i.). Results: HEV viremia persisted for 11 weeks p.i. HEV RNA was detected in the liver, small intestine, and colon at necropsy. Histological analysis revealed liver inflammation and fibrosis. Several mutations selected in the HEV genome were associated with compartmentalization in the feces and intestinal tissues, consistent with the hypothesis of extrahepatic replication in the digestive tract. Antiviral responses were characterized by a downregulation of IFN pathways in the liver, despite an upregulation of RIG-I and ISGs in the blood and liver. Conclusions: We developed a pig model of chronic hepatitis E that reproduced the major hallmarks of this disease. This model revealed a compartmentalization of HEV genomes in the digestive tract and a downregulation of innate immune responses in the liver. These original features highlight the relevance of our model for studies of the pathogenesis of chronic hepatitis E and for validating future treatments. Export

1 July 2010 in Anti-Infective Agents
Verified
Journal Article
Closed access
PDF file
DKDominique Kerboeuf
Dominique Kerboeuf
MRMickaël Riou
Mickaël Riou
CNCedric Neveu
Cedric Neveu
MIMohamed Issouf
Mohamed Issouf
Helminths are responsible for numerous health problems in both animals and human around the world. In animals, they cause heavy losses in meat, milk and wool production. The only available mean for controlling the resulting diseases are currently treatments with anthelmintics. Unfortunately, many cases of drug resistance have emerged affecting most of the antiparasitic compounds. While attempts are made for finding new groups of drugs, efforts are also made for understanding the underlying mechanisms of drug resistance or reduced efficacy of anthelmintics. Among the mechanisms, the identification of alterations in drug transport, specifically in active transport due to protein transporters, has been the aim of several recent investigations. Mechanisms very similar to those responsible for failures in cancer therapy have been described. Many progresses in genomic analyses have been made, especially thanks to the model nematode Caenorhabditis elegans. A better knowledge of the role of these transporters in the efficacy of anthelmintics should conduct to the development of new strategies in antiparasitic therapy and the identification of effective and non-toxic inhibitors of the efflux pumps of helminths.

12 September 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NCNicolas CHOPIN
Nicolas CHOPIN
JBJulien Bosson
Julien Bosson
SIShinya Iikawa
Shinya Iikawa
SPStéphane Picot
Stéphane Picot
ABAnne-Lise Bienvenu
Anne-Lise Bienvenu
MMMaurice Médebielle
Maurice Médebielle

9 February 2024 in Vaccine
Verified
Journal Article
Open access
AAAria Aminzadeh
Aria Aminzadeh
LHLuuk Hilgers
Luuk Hilgers
PPPeter Paul Platenburg
Peter Paul Platenburg
MRMickaël Riou
Mickaël Riou
NPNoémie Perrot
Noémie Perrot
Rene JørgensenRene Jørgensen
Rene Jørgensen
Clostridioides difficile infection (CDI) is a serious healthcare-associated disease, causing symptoms such as diarrhea and pseudomembranous colitis. The major virulence factors responsible for the disease symptoms are two secreted cytotoxic proteins, TcdA and TcdB. A parenteral vaccine based on formaldehyde-inactivated TcdA and TcdB supplemented with alum adjuvant, has previously been investigated in humans but resulted in an insufficient immune response. In search for an improved response, we investigated a novel toxin inactivation method and a novel, potent adjuvant. Inactivation of toxins by metal-catalyzed oxidation (MCO) was previously shown to preserve neutralizing epitopes and to annihilate reversion to toxicity. The immunogenicity and safety of TcdA and TcdB inactivated by MCO and combined with a novel carbohydrate fatty acid monosulphate ester-based (CMS) adjuvant were investigated in rabbits. Two or three intramuscular immunizations generated high serum IgG and neutralizing antibody titers against both toxins. The CMS adjuvant increased antibody responses to both toxins while an alum adjuvant control was effective only against TcdA. Systemic safety was evaluated by monitoring body weight, body temperature, and analysis of red and white blood cell counts shortly after immunization. Local safety was assessed by histopathologic examination of the injection site at the end of the study. Body weight gain was constant in all groups. Body temperature increased up to 1 ˚C one day after the first immunization but less after the second or third immunization. White blood cell counts, and percentage of neutrophils increased one day after immunization with CMS-adjuvanted vaccines, but not with alum. Histopathology of the injection sites 42 days after the last injection did not reveal any abnormal tissue reactions. From this study, we conclude that TcdA and TcdB inactivated by MCO and combined with CMS adjuvant demonstrated promising immunogenicity and safety in rabbits and could be a candidate for a vaccine against CDI.

31 July 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
LFLuca Freddi
Luca Freddi
AVAcacia Ferreira Vicente
Acacia Ferreira Vicente
EPElodie Petit
Elodie Petit
MRMaëline Ribeiro
Maëline Ribeiro
YGYvette Game
Yvette Game
CPClaire Ponsart
Claire Ponsart
France has been officially free of bovine brucellosis since 2005. Nevertheless, in 2012, as the source of two human cases, a bovine outbreak due to B. melitensis biovar 3 was confirmed in the French Alpine Bargy massif, due to a spillover from wild, protected Alpine ibex (Capra ibex). In order to reduce high Brucella prevalence in the local ibex population, successive management strategies have been implemented. Lateral flow immunochromatography assay (LFIA) was thus identified as a promising on-site screening test, allowing for a rapid diagnosis far from the laboratory. This study compared a commercial LFIA for brucellosis diagnosis with the WOAH-recommended tests for small ruminants (i.e., Rose Bengal test (RBT), Complement fixation test, (CFT) and Indirect ELISA, (iELISA)). LFIA showed the same analytical sensitivity as iELISA on successive dilutions of the International Standard anti-Brucella melitensis Serum (ISaBmS) and the EU Goat Brucella Standard Serum (EUGBSS). Selectivity was estimated at 100% when vaccinated ibex sera were analyzed. When used on samples from naturally infected ibex, LFIA showed high concordance, as well as relative sensitivity and specificity (>97.25%) in comparison with RBT and CFT. This work shows high reliability and ensures a better standardization of LFIA testing for wild ruminants.